MetaCap

Tempest Therapeutics Inc. (TPST)

NASDAQ: TPSTHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.287-0.0189 (-6.18%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TPST stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$3.16
52-week range
0.28 – 4.22
Day range
0.2803 – 0.2968
Volume / Avg
145.31K / 2.56M
Beta
—

52-week range

$0.28$4.22

TPST stock today

Tempest Therapeutics (TPST) closed at $0.287 on Nov 20, down 6.18% (-$0.0189), versus the S&P 500's 3.70% decline. Trading was light, with 145.31K shares changing hands, about 6% of the average daily volume. Shares are 93.2% below their 52-week high of $4.22, set on Nov 24, 2025 and 2.5% above the 52-week low of $0.28, near the bottom of the past year's range.

TPST is down 90.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 91.8%. Tempest Therapeutics has posted a net loss over the last twelve months (EPS of -$3.16), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Tempest Therapeutics

Company profile

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Matthew Angel Ph.D.
Headquarters
Brisbane, CA
Employees
4

Financial highlights

Full financials

Tempest Therapeutics reported a net loss of $26.3 million, compared with a loss of $41.8 million a year earlier. Diluted earnings per share came in at -$6.33.

Tempest Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-26.26M$-41.84M$-29.49M$-35.71M$-28.30M
EPS (diluted)$-6.33$-19.50$-1.91$-3.09$-7.47

Analyst forecast

Forecast

Consensus (1 analysts)

strong_buy

Avg. price target

$7.00+2339.02%

  • Strong buy 0
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.21 vs $-0.32
Surprise
+34.38%

TPST news

All TPST news

Tempest Therapeutics peers

Health Care sector
TPST peer companies
CompanyPrice% ChgMarket capCompare
LGVNLongeveron Inc. Class A1.66-8.79%$5.60Mvs TPST
XCURExicure Inc.0.9001-12.82%$5.89Mvs TPST
TOVXTheriva Biologics Inc.0.12-6.25%$5.51Mvs TPST
ENVBEnveric Biosciences Inc.1.35-4.26%$6.04Mvs TPST
UPCUniverse Pharmaceuticals Inc. Class A1.08-20.59%$5.43Mvs TPST
ADXNAddex Therapeutics Ltd ADR3.47+2.06%$6.08Mvs TPST
CNSPCNS Pharmaceuticals Inc.3.56-12.75%$5.25Mvs TPST
ACXPAcurx Pharmaceuticals Inc.1.04+0.97%$6.30Mvs TPST

Indexes, lists and sector

Tempest Therapeutics stock FAQ

What is Tempest Therapeutics's stock price today?

TPST last traded at $0.287 as of Nov 20, 4:00 PM EST, down 6.18% on the day. Prices are delayed at least 15 minutes.

Does Tempest Therapeutics pay a dividend?

No. Tempest Therapeutics does not currently pay a regular cash dividend.

Who is Tempest Therapeutics's CEO?

Dr. Matthew Angel Ph.D. is the chief executive officer of Tempest Therapeutics Inc., which has about 4 employees.

Has TPST ever split its stock?

Yes. The most recent TPST stock split was a 1-for-13 split on Apr 9, 2025, one of 3 splits on record.

What is the TPST 52-week high?

The 52-week high for TPST is $4.22 and the 52-week low is $0.28. The stock is currently 93.2% below its high.

Compare TPST